Jul 08, 2025 8:00am EDT OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
Jun 25, 2025 11:00am EDT OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
Jun 25, 2025 8:00am EDT OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
Jun 09, 2025 8:00am EDT OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development
Apr 30, 2025 4:05pm EDT OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results
Apr 04, 2025 8:00am EDT OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
Mar 17, 2025 8:00am EDT OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
Mar 11, 2025 9:00am EDT Labcorp Announces Acquisition of Select Assets of BioReference Health’s Innovative Oncology and Related Clinical Testing Services Businesses